KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to -$2.5 billion.

  • Regeneron Pharmaceuticals' Cash from Investing Activities rose 29.86% to -$402.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$498.8 million, marking a year-over-year increase of 82.71%. This contributed to the annual value of -$2.5 billion for FY2024, which is 22.51% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' Cash from Investing Activities stood at -$2.5 billion, which was up 22.51% from -$3.2 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Cash from Investing Activities' 5-year high stood at -$70.6 million during FY2020, with a 5-year trough of -$5.4 billion in FY2021.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Cash from Investing Activities value was -$3.2 billion (recorded in 2023), while the average stood at -$3.1 billion.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 96.52% in 2020, then slumped by 7,527.05% in 2021.
  • Regeneron Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$70.6 million in 2020, then tumbled by 7,527.05% to -$5.4 billion in 2021, then grew by 29.72% to -$3.8 billion in 2022, then increased by 15.84% to -$3.2 billion in 2023, then grew by 22.51% to -$2.5 billion in 2024.